Underlying Causes and Treatment Modalities for Neurological Deficits in COVID-19 and Long-COVID

Abdul Mannan Baig; Nigel H. Greig; Joachim Gerlach; Prakash Salunke; Mark Fabrowski; Valentina Viduto; Tazeen Ali

doi:10.1021/acschemneuro.2c00482

Underlying Causes and Treatment Modalities for Neurological Deficits in COVID-19 and Long-COVID

Abdul Mannan Baig, Nigel H. Greig, Joachim Gerlach, Prakash Salunke, Mark Fabrowski, Valentina Viduto, Tazeen Ali

School of Nursing & Midwifery, Pakistan

Research output: Contribution to journal › Article › peer-review

2 Citations (Scopus)

Abstract

With reports of diverse neurological deficits in the acute phase of COVID-19, there is a surge in neurological findings in Long-COVID-a protracted phase of SARS-CoV-2 infection. Very little is known regarding the pathogenic mechanisms of Neuro-COVID in the above two settings in the current pandemic. Herein, we hint toward the possible molecular mechanism that can contribute to the signs and symptoms of patients with neurological deficits and possible treatment and prevention modalities in the acute and chronic phases of COVID-19.

Original language	English (UK)
Pages (from-to)	2934-2938
Number of pages	5
Journal	ACS Chemical Neuroscience
Volume	13
Issue number	20
DOIs	https://doi.org/10.1021/acschemneuro.2c00482
Publication status	Published - 19 Oct 2022

Keywords

COVID-19
Long-COVID
Neuro-COVID
Neurological Deficits
Post-COVID-19 sequelae
Treatment Long-COVID

Access to Document

10.1021/acschemneuro.2c00482

Cite this

@article{a1f435942e3741788a8dd6c56ba08f5b,

title = "Underlying Causes and Treatment Modalities for Neurological Deficits in COVID-19 and Long-COVID",

abstract = "With reports of diverse neurological deficits in the acute phase of COVID-19, there is a surge in neurological findings in Long-COVID-a protracted phase of SARS-CoV-2 infection. Very little is known regarding the pathogenic mechanisms of Neuro-COVID in the above two settings in the current pandemic. Herein, we hint toward the possible molecular mechanism that can contribute to the signs and symptoms of patients with neurological deficits and possible treatment and prevention modalities in the acute and chronic phases of COVID-19.",

keywords = "COVID-19, Long-COVID, Neuro-COVID, Neurological Deficits, Post-COVID-19 sequelae, Treatment Long-COVID",

author = "Baig, \{Abdul Mannan\} and Greig, \{Nigel H.\} and Joachim Gerlach and Prakash Salunke and Mark Fabrowski and Valentina Viduto and Tazeen Ali",

note = "Publisher Copyright: {\textcopyright} 2022 American Chemical Society.",

year = "2022",

month = oct,

day = "19",

doi = "10.1021/acschemneuro.2c00482",

language = "English (UK)",

volume = "13",

pages = "2934--2938",

journal = "ACS Chemical Neuroscience",

issn = "1948-7193",

publisher = "American Chemical Society",

number = "20",

}

TY - JOUR

T1 - Underlying Causes and Treatment Modalities for Neurological Deficits in COVID-19 and Long-COVID

AU - Baig, Abdul Mannan

AU - Greig, Nigel H.

AU - Gerlach, Joachim

AU - Salunke, Prakash

AU - Fabrowski, Mark

AU - Viduto, Valentina

AU - Ali, Tazeen

PY - 2022/10/19

Y1 - 2022/10/19

N2 - With reports of diverse neurological deficits in the acute phase of COVID-19, there is a surge in neurological findings in Long-COVID-a protracted phase of SARS-CoV-2 infection. Very little is known regarding the pathogenic mechanisms of Neuro-COVID in the above two settings in the current pandemic. Herein, we hint toward the possible molecular mechanism that can contribute to the signs and symptoms of patients with neurological deficits and possible treatment and prevention modalities in the acute and chronic phases of COVID-19.

AB - With reports of diverse neurological deficits in the acute phase of COVID-19, there is a surge in neurological findings in Long-COVID-a protracted phase of SARS-CoV-2 infection. Very little is known regarding the pathogenic mechanisms of Neuro-COVID in the above two settings in the current pandemic. Herein, we hint toward the possible molecular mechanism that can contribute to the signs and symptoms of patients with neurological deficits and possible treatment and prevention modalities in the acute and chronic phases of COVID-19.

KW - COVID-19

KW - Long-COVID

KW - Neuro-COVID

KW - Neurological Deficits

KW - Post-COVID-19 sequelae

KW - Treatment Long-COVID

UR - https://www.scopus.com/pages/publications/85139383857

U2 - 10.1021/acschemneuro.2c00482

DO - 10.1021/acschemneuro.2c00482

M3 - Article

C2 - 36190929

AN - SCOPUS:85139383857

SN - 1948-7193

VL - 13

SP - 2934

EP - 2938

JO - ACS Chemical Neuroscience

JF - ACS Chemical Neuroscience

IS - 20

ER -

Underlying Causes and Treatment Modalities for Neurological Deficits in COVID-19 and Long-COVID

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this